Skip to main content
SpringerLink
Log in

Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review

  • Protocol
  • First Online:
Antibody-Drug Conjugates

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1045))

Abstract

Biological therapies play an increasing role in cancer treatment, although the number of naked antibodies showing clinical efficacy as single agent remains limited. One way to enhance therapeutic potential of antibodies is to conjugate them to small molecule drugs. This combination is expected to bring together the benefits of highly potent drugs on the one hand and selective binders of specific tumor antigens on the other hand. However, designing an ADC is more complex than a simple meccano game, requiring thoughtful combination of antibody, linker, and drugs in the context of a target and a defined cancer indication. Lessons learned from the first-generation antibody–drug conjugate (ADC) and improvement of the technology guided the design of improved compounds which are now in clinical trials. Brentuximab vedotin (Adcetris®), an anti-CD30 antibody conjugated to a potent microtubule inhibitor for the treatment of Hodgkin’s lymphoma and anaplastic large cell lymphomas, is the only marketed ADC today. A total of 27 ADC are currently undergoing clinical trials in both hematological malignancies and solid tumor indications. Among them, T-DM1 (trastuzumab emtansine), an ADC comprised of trastuzumab conjugated to DM1, via a non-cleavable linker, is showing very promising results in phase III for the treatment of HER2-positive refractory/relapsed metastatic breast cancer. Other compounds, such as CMC-544, SAR3419, CDX-011, PSMA-ADC, BT-062, and IMGN901 currently in clinical trials, targeting varied antigens and bearing different linker and drugs, contribute to the learning curve of ADC, as do the discontinued ADC. Current challenges include improvement of the therapeutic index, linked to a careful selection of the targets, a better understanding of ADC mechanism of action, the management and understanding of ADC off-target toxicities, as well as the selection of appropriate clinical settings (patient selection, dosing regimen) where these molecules can bring highest clinical benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413–415

    PubMed  Google Scholar 

  2. Larson RA, Sievers EL, Stadtmauer EA et al (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442–1452

    Article  PubMed  CAS  Google Scholar 

  3. Sievers EL, Larson RA, Stadtmauer EA et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol J Am Soc Clin Oncol 19:3244–3254

    CAS  Google Scholar 

  4. Ricart AD (2011) Antibody–drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res J Am Assoc Cancer Res 17:6417–6427

    Article  CAS  Google Scholar 

  5. Teicher BA (2009) Antibody–drug conjugate targets. Curr Cancer Drug Targets 9:982–1004

    Article  PubMed  CAS  Google Scholar 

  6. Helft PR, Schilsky RL, Hoke FJ et al (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res J Am Assoc Cancer Res 10:4363–4368

    Article  CAS  Google Scholar 

  7. Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol J Am Soc Clin Oncol 21:211–222

    Article  CAS  Google Scholar 

  8. Heider K, Kuthan H, Stehle G et al (2004) CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother CII 53:567–579

    Article  CAS  Google Scholar 

  9. Riechelmann H, Sauter A, Golze W et al (2008) Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44:823–829

    Article  PubMed  CAS  Google Scholar 

  10. Sauter A, Kloft C, Gronau S et al (2007) Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30:927–935

    PubMed  CAS  Google Scholar 

  11. Tijink BM, Buter J, Bree R et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res J Am Assoc Cancer Res 12:6064–6072

    Article  CAS  Google Scholar 

  12. Lapusan S, Vidriales MB, Thomas X et al (2012) Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 30:1121–1131

    Article  PubMed  CAS  Google Scholar 

  13. Chari R, Xie H, Leece B (2005) Preclinical evaluation of an anti-CD33-maytansinoid immunoconjugate, huMy9-6-DM4 (AVE9633) for the targeted therapy of acute myeloid leukemia. Am Assoc Cancer Res, Abstract LB–287

    Google Scholar 

  14. Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98–107

    Article  PubMed  CAS  Google Scholar 

  15. Kratz F, Ajaj KA, Warnecke A (2007) Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs 16:1037–1058

    Article  PubMed  CAS  Google Scholar 

  16. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235–244

    Article  PubMed  CAS  Google Scholar 

  17. Chari RV, Martell BA, Gross JL et al (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 52:127–131

    PubMed  CAS  Google Scholar 

  18. Widdison WC, Wilhelm SD, Cavanagh EE et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392–4408

    Article  PubMed  CAS  Google Scholar 

  19. Doronina SO, Mendelsohn BA, Bovee TD et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114–124

    Article  PubMed  CAS  Google Scholar 

  20. Hamann PR, Hinman LM, Beyer CF et al (2002) An anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13:40–46

    Article  PubMed  CAS  Google Scholar 

  21. Tietze LF, Krewer B (2009) Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies. Anticancer Agent Med Chem 9:304–325

    Article  CAS  Google Scholar 

  22. Ducry L, Stump B (2010) Antibody–drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21:5–13

    Article  PubMed  CAS  Google Scholar 

  23. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA (2006) Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426–4433

    Article  PubMed  CAS  Google Scholar 

  24. Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–784

    Article  PubMed  CAS  Google Scholar 

  25. Erickson HK, Widdison WC, Mayo MF et al (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody–maytansinoid conjugates. Bioconjug Chem 21:84–92

    Article  PubMed  CAS  Google Scholar 

  26. Kellogg BA, Garrett L, Kovtun Y et al (2011) Disulfide-linked antibody–maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 22:717–727

    Article  PubMed  CAS  Google Scholar 

  27. Okeley NM, Miyamoto JB, Zhang X et al (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody–drug conjugate. Clin Cancer Res J Am Assoc Cancer Res 16:888–897

    Article  CAS  Google Scholar 

  28. Kovtun YV, Audette CA, Ye Y et al (2006) Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214–3221

    Article  PubMed  CAS  Google Scholar 

  29. Sanderson RJ, Hering MA, James SF et al (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res J Am Assoc Cancer Res 11:843–852

    CAS  Google Scholar 

  30. Hamblett KJ, Senter PD, Chace DF et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res J Am Assoc Cancer Res 10:7063–7070

    Article  CAS  Google Scholar 

  31. Shen B, Xu K, Liu L et al (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates. Nat Biotechnol 30:184–189

    Article  PubMed  CAS  Google Scholar 

  32. Wakankar A, Chen Y, Gokarn Y et al (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3:161–172

    Article  PubMed  Google Scholar 

  33. Deutsch YE, Tadmor T, Podack ER et al (2011) CD30: an important new target in hematologic malignancies. Leuk Lymphoma 52:1641–1654

    Article  PubMed  CAS  Google Scholar 

  34. Gerber H (2010) Emerging immunotherapies targeting CD30 in Hodgkin’s lymphoma. Biochem Pharmacol 79:1544–1552

    Article  PubMed  CAS  Google Scholar 

  35. Katz J, Janik JE, Younes A (2011) Brentuximab vedotin (SGN-35). Clin Cancer Res J Am Assoc Cancer Res 17:6428–6436

    Article  CAS  Google Scholar 

  36. Younes A (2011) CD30-targeted antibody therapy. Curr Opin Oncol 23:587–593

    Article  PubMed  CAS  Google Scholar 

  37. Furtado M, Rule S (2012) Emerging pharmacotherapy for relapsed or refractory Hodgkin’s lymphoma: focus on brentuximab vedotin. Clin Med Insight Oncol 6:31–39

    CAS  Google Scholar 

  38. Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol J Am Soc Clin Oncol 30:2190–2196

    Article  CAS  Google Scholar 

  39. Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631–637

    Article  PubMed  CAS  Google Scholar 

  40. Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465

    Article  PubMed  CAS  Google Scholar 

  41. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821

    Article  PubMed  CAS  Google Scholar 

  42. Fanale MA, Forero-Torres A, Rosenblatt JD et al (2012) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res J Am Assoc Cancer Res 18:248–255

    Article  CAS  Google Scholar 

  43. Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin and other lymphoma. J Clin Oncol J Am Soc Clin Oncol 30:2183–2189

    Article  CAS  Google Scholar 

  44. Minich SS (2012) Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother 46:377–383

    Article  PubMed  Google Scholar 

  45. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165–184

    PubMed  Google Scholar 

  46. Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol J Am Soc Clin Oncol 28:92–98

    Article  CAS  Google Scholar 

  47. Arteaga CL, Sliwkowski MX, Osborne CK et al (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32

    Article  CAS  Google Scholar 

  48. Tsang RY, Finn RS (2012) Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 106:6–13

    Article  PubMed  CAS  Google Scholar 

  49. Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res 68:9280–9290

    Article  Google Scholar 

  50. Junttila TT, Li G, Parsons K et al (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347–356

    Article  PubMed  CAS  Google Scholar 

  51. Barok M, Tanner M, Koninki K et al (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res BCR 13:R46

    Article  CAS  Google Scholar 

  52. Krop IE, Beeram M, Modi S et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol J Am Soc Clin Oncol 28:2698–2704

    Article  CAS  Google Scholar 

  53. Beeram M, Krop IE, Burris HA et al (2012) A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118:5733–5740

    Article  PubMed  CAS  Google Scholar 

  54. Burris HA, Tibbitts J, Holden SN et al (2011) Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer 11:275–282

    Article  PubMed  CAS  Google Scholar 

  55. Mathew J, Perez EA (2011) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 23:594–600

    Article  PubMed  CAS  Google Scholar 

  56. Lorusso PM, Weiss D, Guardino E et al (2011) Trastuzumab emtansine: a unique antibody–drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res J Am Assoc Cancer Res 17:6437–6447

    Article  CAS  Google Scholar 

  57. Burris HA, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol J Am Soc Clin Oncol 29:398–405

    Article  CAS  Google Scholar 

  58. Krop IE, Lorusso P, Miller KD et al (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol J Am Soc Clin Oncol 30:3234–3241

    Article  CAS  Google Scholar 

  59. Girish S, Gupta M, Wang B et al (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69:1229–1240

    Article  PubMed  CAS  Google Scholar 

  60. Gupta M, Lorusso PM, Wang B et al (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52:691–703

    Article  PubMed  CAS  Google Scholar 

  61. Perez E, Dirix L, Kocsis J et al (2010) Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g). Ann Oncol 21(Suppl 8):viii2, Abstract LBA3

    Google Scholar 

  62. Hurvitz S, Dirix L, Kocsis J et al (2011) Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H + T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976). Eur J Cancer 47:ECCO–ESMO, Abstract 5001

    Google Scholar 

  63. Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791

    Article  PubMed  CAS  Google Scholar 

  64. Tedder TF, Poe JC, Haas KM (2005) CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88:1–50

    Article  PubMed  CAS  Google Scholar 

  65. Shan D, Press OW (1995) Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 154:4466–4475

    PubMed  CAS  Google Scholar 

  66. Wong BY, Dang NH (2010) Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 10:1251–1258

    Article  PubMed  CAS  Google Scholar 

  67. Thomas X (2012) Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs 21:871–878

    Article  PubMed  CAS  Google Scholar 

  68. DiJoseph JF, Goad ME, Dougher MM et al (2004) Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res J Am Assoc Cancer Res 10:8620–8629

    Article  CAS  Google Scholar 

  69. Advani A, Coiffier B, Czuczman MS et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin and other lymphoma: results of a phase I study. J Clin Oncol J Am Soc Clin Oncol 28:2085–2093

    Article  CAS  Google Scholar 

  70. Ogura M, Tobinai K, Hatake K et al (2010) Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 101:1840–1845

    Article  PubMed  CAS  Google Scholar 

  71. DiJoseph JF, Dougher MM, Kalyandrug LB et al (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res J Am Assoc Cancer Res 12:242–249

    Article  CAS  Google Scholar 

  72. Dang N, Smith M, Offner F et al (2009) Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or “aggressive” lymphoma. Blood 114, Abstract 584

    Google Scholar 

  73. Fayad L, Patel H, Verhoef G et al (2008) Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study. Blood 112, Abstract 266

    Google Scholar 

  74. Verhoef G, Dang N, Smith M et al (2010) Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or aggressive lymphomas. Haematologica 95, Abstract 0573

    Google Scholar 

  75. Jabbour E, O’Brien S, Thomas DA, Ravandi F et al (2011) Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50 % in refractory relapse (R–R) acute lymphocytic leukemia (ALL). J Clin Oncol 29, Abstract 6507

    Google Scholar 

  76. Kantarjian H, Thomas D, Jorgensen J et al (2012) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13:403–411

    Article  PubMed  CAS  Google Scholar 

  77. Blanc V, Bousseau A, Caron A et al (2011) SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res J Am Assoc Cancer Res 17:6448–6458

    Article  CAS  Google Scholar 

  78. Younes A, Kim S, Romaguera J et al (2012) Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol J Am Soc Clin Oncol 30:2776–2782

    Article  CAS  Google Scholar 

  79. Coiffier B, Morschhauser F, Dupuis J et al (2012) Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin’s lymphoma (NCT00796731). J Clin Oncol 30, Abstract 8057

    Google Scholar 

  80. Hammer O (2012) CD19 as an attractive target for antibody-based therapy. MAbs 4:571–577

    Google Scholar 

  81. Keir CH, Vahdat LT (2012) The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther 12:259–263

    Article  PubMed  CAS  Google Scholar 

  82. Tse KF, Jeffers M, Pollack VA et al (2006) CR011, a fully human monoclonal antibody–auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res J Am Assoc Cancer Res 12:1373–1382

    Article  CAS  Google Scholar 

  83. Naumovski L, Junutula JR (2010) Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12:248–257

    PubMed  CAS  Google Scholar 

  84. Hamid O, Sznol M, Pavlick A et al (2010) Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody–drug conjugate (ADC), in patients with advanced melanoma. J Clin Oncol 28, Abstract 8525

    Google Scholar 

  85. Szol M, Hamid O, Hwu P et al (2009) Pharmacokinetics of CR011-vcMMAE, an antibody–drug conjugate, in a phase I study of patients with advanced melanoma. J Clin Oncol 27, Abstract 9063

    Google Scholar 

  86. Saleh M, Bendell J, Rose et al (2010) Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE). J Clin Oncol 28, Abstract 1095

    Google Scholar 

  87. Hoashi T, Sato S, Yamaguchi Y et al (2010) Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J 24:1616–1629

    Article  PubMed  CAS  Google Scholar 

  88. Akhtar NH, Pail O, Saran A et al (2012) Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012:973820

    Article  PubMed  Google Scholar 

  89. Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528–539

    Article  PubMed  CAS  Google Scholar 

  90. Chang SS, Reuter VE, Heston WD et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192–3198

    PubMed  CAS  Google Scholar 

  91. Minner S, Wittmer C, Graefen M et al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281–288

    Article  PubMed  Google Scholar 

  92. Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res J Am Assoc Cancer Res 3:81–85

    CAS  Google Scholar 

  93. Wang X, Ma D, Olson WC et al (2011) In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10:1728–1739

    Article  PubMed  CAS  Google Scholar 

  94. Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol J Am Soc Clin Oncol 26:2147–2154

    Article  CAS  Google Scholar 

  95. Petrylak D, Kantoff P, Mega-A et al (2012) Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in men with prostate cancer previously treated with taxane. J Clin Oncol 30, Abstract 107

    Google Scholar 

  96. Petrylak D, Kantoff P, Frank R et al (2011) Prostate-specific membrane antigen antibody–drug conjugate (PSMA ADC): a phase I trial in taxane-refractory prostate cancer. J Clin Oncol 29, Abstract 4550

    Google Scholar 

  97. Petrylak D, Kantoff P, Mega-A et al (2012) Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): a phase 1 trial in castration-resistant metastatic prostate cancer (mCRPC). EORTC-NCI-AACR 47

    Google Scholar 

  98. Wijdenes J, Vooijs WC, Clément C et al (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318–323

    Article  PubMed  CAS  Google Scholar 

  99. Tassone P, Goldmacher VS, Neri P et al (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104:3688–3696

    Article  PubMed  CAS  Google Scholar 

  100. Jagannath S, Chanan-Khan A, Heffner L et al (2011) BT062, an antibody–drug conjugate directed against CD138, shows clinical activity in a phase I study in patients with relapsed or relapsed/refractory multiple myeloma. ASH Annual Meeting, Abstract 305

    Google Scholar 

  101. Lutz RJ, Whiteman KR (2009) Antibody–maytansinoid conjugates for the treatment of myeloma. MAbs 1:548–551

    Article  PubMed  Google Scholar 

  102. Chanan-Khan A, Wolf J, Gharibo M. et al (2009) Phase I study of IMGN901, used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma – a preliminary safety and efficacy analysis. ASH Annual Meeting, Abstract 2883

    Google Scholar 

  103. Woll P, Laurigan P, O'Brien M et al (2009) Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). Mol Cancer Ther 8, Abstract B237

    Google Scholar 

  104. Woll PJ, O’Brien M, Fossella F et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol J Eur Soc Med Oncol ESMO, Abstract 536

    Google Scholar 

  105. Berdeja J, Ailawadhi S, Niesvizky R et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) used in combination with lenalidomide and dexamethasone in patients with CD56-positive multiple myeloma, a preliminary safety and efficacy analysis of the combination. ASH Annual Meeting, Abstract 1934

    Google Scholar 

  106. Berdeja J, Mace J, Lamar R et al (2012) A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). J Clin Oncol 30, Abstract TPS8115

    Google Scholar 

  107. Mao W, Tien J, Goldenberg D et al (2010) Early study on LGR5/GPR49 molecule as a potential colon cancer stem cell target for the antibody conjugated drug treatment. Annual Meeting of the AACR, Abstract 4289

    Google Scholar 

  108. Schliemann C, Neri D (2010) Antibody-based vascular tumor targeting. Recent Results Cancer Res 180:201–216

    Article  PubMed  CAS  Google Scholar 

  109. Terrett J, Devasthali V, Pan C et al (2008) Ptk7 as a direct and tumor stroma target in multiple solid malignancies. Annual Meeting of the AACR, Abstract 1526

    Google Scholar 

  110. Vater C, Manning C, Millar H et al (2008) Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. EORTC-NCI-AACR, Abstract ENA–0399

    Google Scholar 

  111. Thon JN, Devine MT, Begonja AJ et al (2012) High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 120:1975–1984

    Article  PubMed  CAS  Google Scholar 

  112. Kovtun YV, Audette CA, Mayo MF et al (2010) Antibody–maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 70:2528–2537

    Article  PubMed  CAS  Google Scholar 

  113. Erickson HK, Lambert JM (2012) ADME of antibody–maytansinoid conjugates. AAPS J 14:799–805

    Article  PubMed  CAS  Google Scholar 

  114. Erickson HK, Phillips GD, Leipold DD et al (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11:1133–1142

    Article  PubMed  CAS  Google Scholar 

  115. Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2354–2366

    Article  PubMed  CAS  Google Scholar 

  116. Junutula JR, Raab H, Clark S et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932

    Article  PubMed  CAS  Google Scholar 

  117. McDonagh CF, Turcott E, Westendorf L et al (2006) Engineered antibody–drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Design Select PEDS 19:299–307

    Article  CAS  Google Scholar 

  118. Zhao RY, Wilhelm SD, Audette C et al (2011) Synthesis and evaluation of hydrophilic linkers for antibody–maytansinoid conjugates. J Med Chem 54:3606–3623

    Article  PubMed  CAS  Google Scholar 

  119. Moldenhauer G, Salnikov AV, Lüttgau AV et al (2012) Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 104:622–634

    Article  PubMed  CAS  Google Scholar 

  120. Kim KM, McDonagh CF, Westendorf L et al (2008) Anti-CD30 diabody–drug conjugates with potent antitumor activity. Mol Cancer Ther 7:2486–2497

    Article  PubMed  CAS  Google Scholar 

  121. Wittrup KD, Thurber GM, Schmidt MM et al (2012) Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255–268

    Article  PubMed  CAS  Google Scholar 

  122. Annunziata CM, Kohn EC, Lorusso P et al (2012) Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 31:77–84

    Google Scholar 

  123. Milowsky M, Galsky M, George M et al (2006) Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). J Clin Oncol 24, Abstract 4500

    Google Scholar 

  124. Chan SY, Gordon AN, Coleman RE et al (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother CII 52:243–248

    CAS  Google Scholar 

  125. Gillespie AM, Broadhead TJ, Chan SY et al (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol J Eur Soc Med Oncol ESMO 11:735–741

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Anne Bousseau and Laurent Ducry for their helpful suggestions and critical reading of the manuscript.

Author information

Authors and Affiliations

  1. Sanofi Oncology, Vitry-sur-Seine, France

    Ingrid Sassoon & Véronique Blanc

Authors
  1. Ingrid Sassoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Véronique Blanc
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lonza Ltd, Visp, Switzerland

    Laurent Ducry

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Sassoon, I., Blanc, V. (2013). Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review. In: Ducry, L. (eds) Antibody-Drug Conjugates. Methods in Molecular Biology, vol 1045. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-541-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-541-5_1

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-540-8

  • Online ISBN: 978-1-62703-541-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation